EVEROLIMUS
Generic: EVEROLIMUS
Biocon Pharma Inc.Manufacturer
ORALRoute
EVEROLIMUSActive Substance
2025-04-09Original Approval
EVEROLIMUS is FDA application ANDA216140, sponsored by BIOCON PHARMA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
MALIGNANT NEOPLASM PROGRESSION
1,539 reports
2
OFF LABEL USE
1,305 reports
3
DIARRHOEA
1,213 reports
4
DRUG INEFFECTIVE
997 reports
5
FATIGUE
839 reports
6
NAUSEA
768 reports
7
DISEASE PROGRESSION
752 reports
8
DEATH
743 reports
9
PRODUCT USE IN UNAPPROVED INDICATION
742 reports
10
DYSPNOEA
653 reports